Literature DB >> 19704339

Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung.

James C Ho1, David C Lam, Matthew K Wong, Bing Lam, Mary S Ip, Wah K Lam.   

Abstract

Lymphoepithelioma-like carcinoma (LELC) of lung has previously demonstrated good clinical response to 5-fluorouracil containing chemotherapy regimen, similar to the observation in undifferentiated nasopharyngeal carcinoma. Capecitabine, which is converted into active 5-fluorouracil within tumor cells, has been found effective in colorectal, breast, and recently nasopharyngeal carcinomas. We report our experience in five patients with advanced or metastatic LELC of lung who were treated with single agent capecitabine as salvage chemotherapy. The finding of disease control in three of five patients, especially with exceptionally durable stable disease (14.8 months) in one patient, suggests the potential clinical activity of capecitabine in LELC of lung. Future studies on capecitabine-containing chemotherapy regimens in LELC of lung are warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19704339     DOI: 10.1097/JTO.0b013e3181b28f15

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  11 in total

1.  Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature.

Authors:  Chul Kim; Arun Rajan; Pedro A DeBrito; Giuseppe Giaccone
Journal:  Transl Lung Cancer Res       Date:  2016-12

2.  Clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma.

Authors:  Wen-Yang Jiang; Rui Wang; Xu-Feng Pan; Yu-Zhou Shen; Tian-Xiang Chen; Yun-Hai Yang; Jin-Cheng Shao; Lei Zhu; Bao-Hui Han; Jun Yang; Heng Zhao
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 3.  Treatment of Lung Carcinosarcoma and Other Rare Histologic Subtypes of Non-small Cell Lung Cancer.

Authors:  Han Yang; Yongbin Lin; Ying Liang
Journal:  Curr Treat Options Oncol       Date:  2017-08-10

4.  Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome.

Authors:  Chun-Yu Lin; Ying-Jen Chen; Meng-Heng Hsieh; Chih-Wei Wang; Yueh-Fu Fang
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

5.  Primary Lymphoepithelioma-like Carcinoma of the Lung in a 13 year old Girl.

Authors:  Susmita Kundu; Ritabrata Mitra; Anup Majumdar; Sucheta Saha; Swapnendu Misra
Journal:  Oman Med J       Date:  2012-01

6.  Pulmonary lymphoepithelioma-like carcinoma: a Surveillance, Epidemiology, and End Results database analysis.

Authors:  Jiaxi He; Jianfei Shen; Hui Pan; Jun Huang; Wenhua Liang; Jianxing He
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

Review 7.  Primary pulmonary lymphoepithelioma-like carcinoma.

Authors:  Ying Fan; Chenghui Li; Jing Qin; Hongyang Lu
Journal:  Med Oncol       Date:  2020-03-07       Impact factor: 3.064

8.  CD56+ lymphoepithelioma-like carcinoma of the lung: A case report and literature review.

Authors:  Lin Yang; Hua Liang; Li Liu; Lei Guo; Jian-Ming Ying; Su-Sheng Shi; Xing-Sheng Hu
Journal:  World J Clin Cases       Date:  2020-04-06       Impact factor: 1.337

9.  Detection of rearrangement of anaplastic lymphoma kinase (ALK) and mutation of epidermal growth factor receptor (EGFR) in primary pulmonary lymphoepithelioma-like carcinoma.

Authors:  Liang Wang; Yongbin Lin; Qingqing Cai; Hao Long; Yu Zhang; Tiehua Rong; Guowei Ma; Ying Liang
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

10.  A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung.

Authors:  Zhanhong Xie; Laiyu Liu; Xinqing Lin; Xiaohong Xie; Yingying Gu; Ming Liu; Jiexia Zhang; Ming Ouyang; Analyn Lizaso; Hua Zhang; Weineng Feng; Bing Li; Han Han-Zhang; Shuyin Chen; Shiyue Li; Nanshan Zhong; Hao Liu; Chengzhi Zhou; Yinyin Qin
Journal:  Mod Pathol       Date:  2019-10-28       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.